Pharma-Bio Serv (PBSV) EBIAT (2016 - 2026)
Pharma-Bio Serv's EBIAT history spans 17 years, with the latest figure at -$94535.0 for Q1 2026.
- For Q1 2026, EBIAT fell 1207.49% year-over-year to -$94535.0; the TTM value through Jan 2026 reached -$530379.0, up 47.4%, while the annual FY2025 figure was -$637662.0, 50.48% up from the prior year.
- EBIAT reached -$94535.0 in Q1 2026 per PBSV's latest filing, up from -$133272.0 in the prior quarter.
- In the past five years, EBIAT ranged from a high of $526242.0 in Q3 2023 to a low of -$493857.0 in Q4 2024.
- Average EBIAT over 5 years is $28443.4, with a median of -$47148.0 recorded in 2023.
- Peak YoY movement for EBIAT: skyrocketed 107.01% in 2022, then plummeted 1207.49% in 2026.
- A 5-year view of EBIAT shows it stood at $341640.0 in 2022, then plummeted by 113.8% to -$47148.0 in 2023, then tumbled by 947.46% to -$493857.0 in 2024, then skyrocketed by 73.01% to -$133272.0 in 2025, then rose by 29.07% to -$94535.0 in 2026.
- Per Business Quant, the three most recent readings for PBSV's EBIAT are -$94535.0 (Q1 2026), -$133272.0 (Q4 2025), and -$204250.0 (Q3 2025).